원문정보
초록
영어
Monoclonal antibodies have already established a secure position as a very promising strategy
for therapeutics. Advances in genetic engineering have enabled to generate human antibodies
which circumvent the problems of using murine antibodies in human therapy. High specificity
and high affinity are attractive characteristics of antibodies which make them suitable for
clinical applications. Neutralization of antigens, immunological effects, specific delivery of
antibody conjugate to target cells, and direct effects through receptor engagement by antibodies
have been exploited as mechanisms which generate antibody activity. Here, data will be
presented on a series of human antibodies generated using the KM MouseTM that demonstrates
desirable characteristics for therapeutic use including robust biological activity and low toxicity.
The preclinical data for agonistic and antagonistic antibodies to TNF receptor super family
members including TRAIL-R2 and CD40, will be presented. In addition, neutralizing antibody
against influenza virus M2 protein will be also presented.